CCR2 ANTAGONISTS FOR TREATMENT OF FIBROSIS

• US 20100074886A1
• Filed: 10/05/2007
• Published: 03/25/2010
• Est. Priority Date: 10/05/2006
• Status: Abandoned Application

• Current Assignee: Centocor Ortho Biotech Incorporated (Johnson & Johnson)
• Original Assignee: Centocor Ortho Biotech Incorporated (Johnson & Johnson)
• Inventors: Murray, Lynne, Syed, Fahrat, Das, Anuk
• Application Number:
  US12/442,404
• Publication Number:
  US 20100074886A1
• Time in Patent Office: Days
• US Class Current: 424/130.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/12 for cataracts
• CPC Class Codes: A61P 33/12 Schistosomicides
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Anti-MCP-1/CCR2 antagonist therapy is provided for the control or reversal of fibrosis related diseases, including, e.g., but not limited to MCP-1/CCR2 antagonist therapy for the modulation of profibrotic markers associated with fibrotic processes including collagen matrix deposition and alveolar collapse.

Claims

1. A method for inhibiting at least one human monocyte chemoattractant protein-1 (MCP-1) in a patient having at least one form of fibrosis using at least one MCP-1 antagonist, comprising administering an MCP-1 inhibiting effective amount of at least one MCP-1 antagonists.

2. A method of claim 1, wherein said MCP-1 antagonist is selected from a small molecule and a protein.

3. A method of claim 2, wherein said small molecule is selected from indole derivatives, cyclic amine derivatives, ureido derivatives, heterocyclics, anilides, or functional pyrroles with the ability to block CCL2 binding to CCR2B, or inhibition of CCR1 or CCL2 itself.

4. A method of claim 2, wherein said protein is selected from a soluble receptor, an antibody, a peptide, a fragment thereof, or a fusion protein thereof.

5. A method of claim 4, wherein said protein further comprises a compound or protein that increases the serum half life of said protein.

6. A method of claim 4, wherein said antibody comprises at least one variable region comprising at least one heavy chain variable region and at least one light chain, said MCP-1 antibody comprising both heavy chain and light chain variable regions comprising SEQ ID NOS:

27 and 28.

7. A method of claim 4, wherein said antibody comprises at least one heavy chain variable region and at least one light chain variable region, said antibody comprising all of the heavy chain and light chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOS:

6, 7, 9, 13, 14, and 16.

8. A method of claim 4, wherein said antibody comprises at least one variable region comprising at least one heavy chain and at least one light chain, said MCP-1 antibody comprising both heavy chain and light chain variable regions comprising SEQ ID NOS:

27 and 28.

9. A method of claim 4, wherein said antibody comprises at least one heavy chain variable region and at least one light chain variable region, said antibody comprising all of the heavy chain and light chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOS:

6, 7, 9, 13, 14, and 16.

10. A method of claim 4, wherein said antibody comprises at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:

6, 7, 9, 13, 14, and 16.

11. A method of claim 4, wherein said antibody comprises a heavy chain or light chain variable region of at least one of SEQ ID NO:

2-5 further comprising a complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof selected from the group consisting of SEQ ID NO;

6-26; and

, optionally functionally associated with a framework region, further optionally comprising at least CH1, hinge, CH2, or CH3 of an human immunoglobulin.

12. A method of claim 4, wherein said antibody binds MCP-1 with an affinity of at least one selected from at least 10⁻

9M, at least 10<sup>−

10</sup> M, at least 10<sup>−

11</sup> M, or at least 10<sup>−

12</sup>M.

13. A method of claim 4, wherein said antibody substantially modulates at least one activity of at least one MCP-1 polypeptide.

14. A method of claim 1, wherein said small molecule or protein is provided as a composition further comprising at least one pharmaceutically acceptable carrier or diluent.

15. A method of claim 1, wherein said method further comprises administering at least one at least one compound or polypeptide selected from at least one of a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional product, a cytokine, or a cytokine antagonist.

16. A method according to claim 1, wherein said inhibiting effective amount is 0.001-50 mg/kilogram of said cells, tissue, organ or animal.

17. A method according to claim 1, wherein said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

18. A method of claim 1, wherein said fibrosis is organ specific fibrosis or systemic fibrosis.

19. A method of claim 18, wherein said organ specific fibrosis is associated with at least one of lung fibrosis, liver fibrosis, kidney fibrosis, heart fibrosis, vascular fibrosis, skin fibrosis, eye fibrosis, bone marrow fibrosis or other fibrosis.

20. A method of claim 19, wherein said lung fibrosis is associated with at least one of drug induced pulmonary fibrosis, asthma, sarcoidosis or chronic obstructive pulmonary disease.

21. A method of claim 19, wherein said liver fibrosis is associated with at least one of cirrhosis, schistomasomiasis or cholangitis.

22. A method of claim 21, wherein said cirrhosis is selected from post-hepatitis C cirrhosis, primary biliary cirrhosis.

23. A method of claim 22, wherein said cholangitis is sclerosing cholangitis.

24. A method of claim 19, wherein said kidney fibrosis is associated with lupus glomeruloschelerosis.

25. A method of claim 19, where said heart fibrosis is associated with at least one type of myocardial infarction.

26. A method of claim 19, wherein said vascular fibrosis is associated with at least one of postangioplasty arterial restenosis, or atherosclerosis.

27. A method of claim 19, wherein said skin fibrosis is associated with at least one of keloid, or nephrogenic fibrosing dermatopathy.

28. A method of claim 19, wherein said eye fibrosis is associated with at least one of retro-orbital fibrosis, postcataract surgery or proliferative vitreoretinopathy.

29. A method of claim 19, wherein said bone marrow fibrosis is associated with at least one of idiopathic myelofibrosis or drug induced myelofibrosis.

30. A method of claim 19, wherein said other fibrosis is selected from Peyronie'"'"'s disease, Dupuytren'"'"'s contracture or dermatomyositis.

31. A method of claim 18, wherein said systemic fibrosis is selected from systemic sclerosis and graft versus host disease.

32. (canceled)